Publications by authors named "Alaa Din Abdin"

9 Publications

  • Page 1 of 1

[Pronounced band keratopathy in Refsum's syndrome].

Ophthalmologe 2021 Jun 9. Epub 2021 Jun 9.

Klinik für Augenheilkunde, Universitätsklinikum des Saarlandes UKS, Kirrberger Str. 100, 66421, Homburg/Saar, Deutschland.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00347-021-01428-yDOI Listing
June 2021

[Uniform classification of the pachychoroid spectrum disorders].

Ophthalmologe 2021 Aug 26;118(8):865-878. Epub 2021 Apr 26.

Klinik für Augenheilkunde, Universitätsklinikum des Saarlandes UKS, Kirrberger Str. 100, Gebäude 22, 66421, Homburg/Saar, Deutschland.

Pachychoroid spectrum disorders are characterized by a thickening of the choroid. The spectrum includes pachychoroid pigment epitheliopathy (PPE), central serous chorioretinopathy (CCS), pachychoroid neovasculopathy (PNV), polypoidal choroidal vasculopathy (PCV)/aneurysmal type 1 choroidal neovascularization (ACNV-1), focal choroidal excavation (FCE) and peripapillary pachychoroid syndrome (PPS). If the choroid is thickened and there is a pathological alteration in the retinal pigment epithelium, the diagnosis is PPE; if the thickened choroid is accompanied by subretinal fluid, the diagnosis is CCS; if choroidal neovascularization is present, the diagnosis is PNV; if accompanied by aneurysms, the diagnosis is ACNV‑1. The PPE, CCS, PNV and ACNV‑1 were formerly regarded as independent disease entities but can be classified into four forms of a single disease family, pachychoroid macular disease.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00347-021-01379-4DOI Listing
August 2021

[Complete visual recovery after Nd:YAG laser polishing of the anterior surface of the intraocular lens].

Ophthalmologe 2021 Apr 15. Epub 2021 Apr 15.

Klinik für Augenheilkunde, Universitätsklinikum des Saarlandes (UKS), Homburg/Saar, Deutschland.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00347-021-01373-wDOI Listing
April 2021

[Acute binocular visual loss due to basilar artery aneurysm-induced subarachnoid hemorrhage].

Ophthalmologe 2021 Feb 8. Epub 2021 Feb 8.

Klinik für Neuroradiologie, Universitätsklinikum des Saarlandes UKS, Homburg/Saar, Deutschland.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00347-021-01329-0DOI Listing
February 2021

[Unilateral Irregularities in the Macular Pigment Epithelium in a 38-Year-Old Patient - "Acute Retinal Pigment Epitheliitis"].

Klin Monbl Augenheilkd 2020 Oct 9. Epub 2020 Oct 9.

Klinik für Augenheilkunde, Universitätsklinikum des Saarlandes, Homburg/Saar.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-1241-4521DOI Listing
October 2020

Eplerenone for treatment of chronic central serous chorioretinopathy.

Eur J Ophthalmol 2021 Jul 27;31(4):1885-1891. Epub 2020 Aug 27.

Department of Ophthalmology, Saarland University Medical Center UKS, Homburg/Saar, Germany.

Purpose: To assess the morphological and functional outcome of oral eplerenone for treatment of patients with chronic central serous chorioretinopathy (CSC) in a real life experience.

Patients And Methods: In this retrospective study, we reviewed the clinical files of 30 patients with chronic CSC. All patients were treated with eplerenone for a period of 6 weeks or 3 months depending on the clinical response. Main outcome measures included: best corrected visual acuity (BCVA), central macular thickness (CMT) and height of the subretinal fluid (SRF). Comparisons between responders and non-responders were performed to identify factors that were predictive of the treatment response.

Results: All patients were treated with eplerenone 18 ± 20 weeks after onset of the first symptoms. BCVA (LogMAR) improved from 0.2 ± 0.2 to 0.13 ± 0.18 at 6 weeks ( = 0.01) and to 0.09 ± 0.15 at 3 months ( = 0.01). Mean CMT decreased from 409 ± 136 to 323 ± 87 µm at 6 weeks ( = 0.001) and to 298 ± 98 µm at 3 months ( = 0.01). Mean height of SRF decreased from 153 ± 126 to 73 ± 79 µm at 6 weeks ( = 0.001) and to 49 ± 88 µm at 3 months ( = 0.005). Complete resolution of SRF was achieved in 20 patients after 3 months (67%). Reported stress in the medical history was the only statistical significant predictive factor associated with a positive treatment response.

Conclusion: This study showed a statistically significant improvement of the best corrected visual acuity and a significant reduction of macular thickness and subretinal fluid in patients with chronic CSC treated with oral eplerenone, especially in patients under stress.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1120672120952648DOI Listing
July 2021

Recurrent fungal endophthalmitis after intravitreal injections of bevacizumab.

Am J Ophthalmol Case Rep 2020 Mar 7;17:100591. Epub 2020 Jan 7.

Department of Ophthalmology, Saarland University Medical Center UKS, 66421, Homburg/Saar, Germany.

Purpose: We intend to describe an uncommon case of recurrent post-cataract fungal endophthalmitis after intravitreal injections of Bevacizumab.

Observations: A 73-year-old male, who underwent an uncomplicated cataract surgery 8 months ago, presented to our department with postoperative endophthalmitis 5 days after his fifth intravitreal injection (IVI) of bevacizumab for treatment of cystoid macula edema caused by central retinal venous occlusion 6 months ago. The visual acuity (VA) was 0.1 (20/200). The patient underwent an emergency pars plana vitrectomy. Culture of vitreous tap was negative. Eight weeks later, the patient presented again with recurrent endophthalmitis 2 days after his sixth IVI of bevacizumab. VA was hand motion. The patient was treated with an emergency anterior and posterior segment washout with intracapsular posterior intraocular lens (pIOL) extraction. Culture of pIOL revealed fungi in the capsular bag. Six months later, clinical findings were stable with no signs of intraocular inflammation, VA was 0.3 (20/60).

Conclusions And Importance: we assume that this is a rare case of chronic late-onset post-cataract fungal endophthalmitis, which was activated by repeated intravitreal injections of Bevacizumab.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajoc.2020.100591DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206407PMC
March 2020

Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.

Graefes Arch Clin Exp Ophthalmol 2019 Aug 29;257(8):1671-1677. Epub 2019 May 29.

Department of Ophthalmology, Saarland University Medical Center UKS, KirrbergerStrasse 100, Bldg. 22, 66421, Homburg, Saar, Germany.

Purpose: To assess the morphological and functional outcome and stability of the "treat and extend" protocol using aflibercept compared to ranibizumab for the treatment of eyes with neovascular age-related macular degeneration.

Patients And Methods: This retrospective study included 100 eyes of 94 patients with primary onset neovascular age-related macular degeneration followed up for 12 months. We studied two groups of eyes: group 1, 50 eyes treated with 0.5 mg/0.05 mL ranibizumab and group 2, 50 eyes treated with 2.0 mg/0.05 mL aflibercept. During the first year, all eyes received 3 aflibercept or ranibizumab injections monthly as upload phase. Then, eyes were treated with a treat and extend algorithm. Main outcome measures included: best corrected visual acuity (BCVA), central macular thickness (CMT), and the number of injections. In addition, we compared recurrence rates between the two groups.

Results: BCVA (log MAR) in group 1 vs group 2 was 0.54 ± 0.31 vs 0.49 ± 0.30 (p = 0.38) before treatment and 0.49 ± 0.33 vs 0.47 ± 0.32 (p = 0.85) after treatment. The visual improvement (decimal) was 0.05 ± 0.13 vs 0.04 ± 0.12 (p = 0.91). CMT in group 1 vs group 2 was 375.6 ± 98.3 μm vs 369.6 ± 103.7 μm (p = 0.73) before treatment and 306.3 ± 71.8 μm vs 294.8 ± 96 μm (p = 0.54) after treatment. The decrease in CMT was 69.3 ± 93 μm vs 74.8 ± 96 μm (p = 0.77). The number of injections/eye after upload phase in group 1 vs group 2 was 5.88 ± 1.4 vs 6.16 ± 1.3 (p = 0.25). Finally, major recurrence rates were statistically significantly different between the two groups (2% vs 6%, p = 0.04).

Conclusions: Significant differences regarding BCVA, central macular thickness, and the number of injections were not found between aflibercept and ranibizumab during the first year following the treat and extend protocol. However, the significantly higher major recurrence rates in the aflibercept group after extending the treatment interval to 10 weeks might suggest that aflibercept should better not to be used in longer than 8 weeks intervals during the first year of treatment.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00417-019-04360-9DOI Listing
August 2019

[Advantages of a designated IVI center for a German university eye hospital].

Ophthalmologe 2020 Jan;117(1):50-57

Klinik für Augenheilkunde, Universitätsklinikum des Saarlandes UKS, 66421, Homburg/Saar, Deutschland.

Background: Since 2016, a designated center for the intravitreal injections (IVI) has been established at the department of ophthalmology. Many aims had supported the project of moving IVIs from the main operations theater. This study aimed to assess the practicality and feasibility of such a move.

Methods: In this IVI center, only patients with macular diseases are treated. The premises are arranged directly next to each other. The standardized treatment process starts with registration. Parallel to the formalities, a refraction test is carried out. If necessary optical coherence tomography (OCT) is carried out and then a full eye examination is performed by a doctor. Afterwards, a specialist/consultant decides on the subsequent treatment strategy. The injection takes place in an adjacent standard designated operating room. Patients are handed the computer-generated discharge letters immediately after the procedure and further appointments are booked on discharge.

Results: Despite a 25% increase in the number of IVIs to more than 4000 IVIs per year over the last 2 years, advantages from the establishment of the designated center have resulted as follows: optimal care through precise treatment systems and shorter waiting times. From July to August 2018, 85% of voluntarily participating patients pressed the green or light green smiley face on the "HappyOrNot smiley terminal system". Pressure is taken off the regular outpatient macular consultation service, fixed and direct contact person, pressure is taken off the main operations theater with a significant increase in the diagnosis-related groups (DRG) revenues of 900,000 € and easily accessible database for statistical and scientific purposes.

Conclusion: The designated center proved to be an extremely useful and beneficial one-stop center (IVI carrousel) for patients requiring IVI and macular consultations. It significantly released the pressure on both the outpatient department and the outpatient operation center.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00347-019-0911-5DOI Listing
January 2020
-->